XFOR X4 PHARMACEUTICALS INC.

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management team will participate in a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 at 10:00 a.m. ET in Miami, FL.

A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: .

About X4 Pharmaceuticals

X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is commercially available in the U.S. as XOLREMDI® in its first indication. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit .

X4 Investor Contact:

Remy Bernarda

Jenny Kobin

IR Advisory Solutions

Source: X4 Pharmaceuticals, Inc.



EN
04/03/2026

Underlying

XFORX4 PHARMACEUTICALS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on X4 PHARMACEUTICALS INC.

 PRESS RELEASE
Free
XFOR X4 PHARMACEUTIC...

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Gl...

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management team will participate in a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 at 10:00 a.m. ET in Miami, FL. A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: . About X4 Pharmaceuticals X4 Pharmaceuticals is a compa...

9h / 28m 1 EN
 PRESS RELEASE
Free
XFOR X4 PHARMACEUTIC...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing R...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on February 27, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards c...

March 2, 2026 1 EN
 PRESS RELEASE
Free
XFOR X4 PHARMACEUTIC...

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recomme...

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome - Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorization, under exceptional circumstances, of mavorixafor for th...

February 27, 2026 1 EN
 PRESS RELEASE
Free
XFOR X4 PHARMACEUTIC...

X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Bi...

X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026 BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026 in New York. The X4 team will hold a fireside chat on February 12th at 12:30 p.m. ET and will be available for one-on-one meetings with investors. A webcast of the fireside chat will be available under the “Events and Present...

February 3, 2026 1 EN
 PRESS RELEASE
Free
XFOR X4 PHARMACEUTIC...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Ru...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 30, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awar...

February 2, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch